These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31098863)

  • 1. Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer.
    Jung M; Park KH; Kim HM; Kim TS; Zhang X; Park SM; Beom SH; Kim HS; Cheong JH; Chung HC; Soong J; Lin SC; Rha SY
    Gastric Cancer; 2019 Nov; 22(6):1153-1163. PubMed ID: 31098863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy.
    Siddiqui-Jain A; Bliesath J; Macalino D; Omori M; Huser N; Streiner N; Ho CB; Anderes K; Proffitt C; O'Brien SE; Lim JK; Von Hoff DD; Ryckman DM; Rice WG; Drygin D
    Mol Cancer Ther; 2012 Apr; 11(4):994-1005. PubMed ID: 22267551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer.
    Kim HM; Jeong I; Kim HJ; Kang SK; Kwon WS; Kim TS; Park KH; Jung M; Soong J; Lin SC; Chung HC; Rha SY
    Anticancer Res; 2018 Nov; 38(11):6171-6180. PubMed ID: 30396934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
    Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
    BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Casein kinase 2 inhibitor CX-4945 elicits an anti-Warburg effects through the downregulation of TAp73 and inhibits gastric tumorigenesis.
    Tang S; Yuan Y; Liu Z; He Y; Pan D
    Biochem Biophys Res Commun; 2020 Oct; 530(4):686-691. PubMed ID: 32771361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
    Chen F; Huang X; Wu M; Gou S; Hu W
    Cancer Lett; 2017 Jan; 385():168-178. PubMed ID: 27793693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.
    Bian Y; Han J; Kannabiran V; Mohan S; Cheng H; Friedman J; Zhang L; VanWaes C; Chen Z
    Int J Biol Sci; 2015; 11(4):411-22. PubMed ID: 25798061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
    Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
    Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer.
    Kang SK; Bae HJ; Kwon WS; Kim TS; Kim KH; Park S; Yu SY; Hwang J; Park J; Chung HC; Rha SY
    Cell Oncol (Dordr); 2021 Dec; 44(6):1387-1403. PubMed ID: 34791636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-catenin.
    Kendall JJ; Chaney KE; Patel AV; Rizvi TA; Largaespada DA; Ratner N
    Oncotarget; 2016 Aug; 7(33):53191-53203. PubMed ID: 27448963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
    Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
    Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.
    Bliesath J; Huser N; Omori M; Bunag D; Proffitt C; Streiner N; Ho C; Siddiqui-Jain A; O'Brien SE; Lim JK; Ryckman DM; Anderes K; Rice WG; Drygin D
    Cancer Lett; 2012 Sep; 322(1):113-8. PubMed ID: 22387988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells.
    So KS; Rho JK; Choi YJ; Kim SY; Choi CM; Chun YJ; Lee JC
    Anticancer Res; 2015 Mar; 35(3):1537-42. PubMed ID: 25750308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.
    Richter A; Sender S; Lenz A; Schwarz R; Hinz B; Knuebel G; Sekora A; Murua Escobar H; Junghanss C; Roolf C
    BMC Cancer; 2020 Mar; 20(1):184. PubMed ID: 32131762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
    Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab in combination with paclitaxel enhances antitumor activity by promoting apoptosis in human epidermal growth factor receptor 2-positive trastuzumab-resistant gastric cancer xenograft models.
    Shu S; Yamashita-Kashima Y; Yanagisawa M; Nakanishi H; Kodera Y; Harada N; Yoshimura Y
    Anticancer Drugs; 2020 Mar; 31(3):241-250. PubMed ID: 31633500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.
    Zheng Y; McFarland BC; Drygin D; Yu H; Bellis SL; Kim H; Bredel M; Benveniste EN
    Clin Cancer Res; 2013 Dec; 19(23):6484-94. PubMed ID: 24036851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond.
    Kim J; Kim SH
    Arch Pharm Res; 2012 Aug; 35(8):1293-6. PubMed ID: 22941473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer.
    Guo XF; Li SS; Zhu XF; Dou QH; Liu D
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):383-394. PubMed ID: 29909520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
    Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
    Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.